Clinical Trials
- Breast Cancer
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer
- Date03/01/2022
- Breast Cancer
A Safety Study of SGN-LIV1A in Breast Cancer Patients
- Ages18 years and older
- GenderFemale only
- Date06/16/2022
- Breast Cancer
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
- Date06/06/2022
- Breast Cancer
I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
- Date02/02/2022
- Breast Cancer
Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial
- Date03/01/2022
- Breast Cancer
A Randomized Phase II Trial Of Circulating Tumor DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
- Date02/01/2022
- Breast Cancer
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
- Date04/06/2022
- Mental Health & Behavioral Research
Imaging mGluR5 and synaptic density in psychiatric disorders
- Ages18 years - 80 years
- GenderBoth
- Date01/11/2017
- Addictive Behavior
Imaging Synaptic Density in Cocaine and Opiate Addiction In Vivo using 11C-UCB-J PET
- Date01/29/2019
- Breast Cancer
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
- Date03/10/2022